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RELESSER is a multicenter hospital-based registry, with a collec-
tion of data from a large, representative sample of adult patients with
SLE (1997 ACR criteria) seen at Spanish rheumatology departments.
The registry includes demographic data, comprehensive descriptions of
clinical manifestations, as well as information about disease activity and
severity, cumulative damage, comorbidities, treatments and mortality,
using variables with highly standardized definitions.
A total of 4.024 SLE patients (91% with 4 ACR criteria) were
included. Ninety percent were women with a mean age at diagnosis of
35.4 years and a median duration of disease of 11.0 years. As expected,
most SLE manifestations were more frequent in SLE patients than in
iSLE ones and every one of the ACR criteria was also associated with
SLE condition; this was particularly true of malar rash, oral ulcers and
renal disorder. The analysis—adjusted by gender, age at diagnosis, and
disease duration—revealed that higher disease activity, damage and
SLE severity index are associated with SLE [OR: 1.14; 95% CI: 1.08–
1.20 (P< 0.001); 1.29; 95% CI: 1.15–1.44 (P< 0.001); and 2.10; 95%
CI: 1.83–2.42 (P< 0.001), respectively]. These results support the
hypothesis that iSLE behaves as a relative stable and mild disease.
SLE patients from the RELESSER register do not appear to differ
substantially from other Caucasian populations and although activity
[median SELENA-SLEDA: 2 (IQ: 0–4)], damage [median SLICC/
ACR/DI: 1 (IQ: 0–2)], and severity [median KATZ index: 2 (IQ: 1–3)]
scores were low, 1 of every 4 deaths was due to SLE activity.
RELESSER represents the largest European SLE registry estab-
lished to date, providing comprehensive, reliable and updated infor-
mation on SLE in the southern European population.
(Medicine 94(1):e267)
Abbreviations: Ab = antibodies, ACR = American College of
Rheumatology, ANA = antinuclear antibodies, BILAG = British
Isles Lupus Assessment Group, CI = confidence intervals, CYC =
cyclophosphamide, DM = diabetes mellitus, iSLE = incomplete
SLE, OR = odds ratio, PHT = pulmonary hypertension, SD =
standard deviation, SELENA-SLEDAI = Safety of Estrogens in
Systemic Lupus Erythematosus National Assessment-SLEDAI,
SER = Spanish Rheumatology Society, SKI = Severity Katz Index,
SLE = systemic lupus erythematosus, SLEDAI = Systemic Lupus
Erythematosus Disease Activity Index, SLICC/ACR DI = Systemic
Lupus International Collaborative Clinics/American College of
Rheumatology Damage Index.
INTRODUCTION
S ystemic lupus erythematosus (SLE) is an autoimmuneinflammatory disease with multiple organ involvement
and remains one of the most frequent systemic rheumatic
diseases.1 In Spain, it has a prevalence of 9 per 10,000 per-
sons.2,3 SLE is a remarkably heterogeneous disease with very
different symptoms and outcomes. In recent years, considerable
efforts have been made to gain a deeper understanding of the
disease and how to best manage it. One such effort involves the
setting up of SLE patient registries similar to those that have
been active in North and South America, as well as in Europe,
since the seventies.4 These registries contain a large number of
subjects and reflect a real-world setting for lupus patients. Data
obtained from these lupus registries are essential for planning,
designing, and conducting clinical lupus studies.
The severity of SLE may vary considerably from one
population to another and the Task Force of the EULAR
Ru´a-Figueroa et alStanding Committee for International Clinical Studies has
included this topic in its suggested research agenda.5 With
the aim of obtaining amore representative, accurate information
2 | www.md-journal.comdatabase about SLE in the southern European population, the
Spanish Rheumatology Society (SER) has established a multi-
center registry of patients with SLE known as RELESSER
(Spanish Rheumatology Society SLE Registry), which is the
largest European SLE registry mounted thus far. It offers
comprehensive, reliable, and updated information about this
complex disease, and is being carried out in two phases. The
first part of the registry (RELESSER-T), with cross-sectional
data recording has already completed the enrolment process.
There was, however, a subgroup of patients that did not
meet the 1997 SLE ACR criteria but that presented symptoms
and/or laboratory results which often led to the clinician diag-
nosing them as SLE patients.6–8 As there are relatively few
studies concerning these types of patients, it was considered
worthwhile to include them in the Spanish registry. The avail-
ability of a large and well-characterized SLE population via
RELESSER provides an excellent opportunity to compare, in
detail, both of the patient groups included in the register.
The purposes of the present analysis were to describe the
demographic features, cumulative clinical manifestations,
severity, treatments, and complications of RELESSER patients
at the time of the last medical visit, focusing on the differences
between patients who fulfilled 4 or more of the 1997-ACR SLE
criteria9 and those who did not (‘‘incomplete SLE’’: iSLE). We
also compared these cross-sectional data from RELESSER with
those from other large cohorts around the world.
METHODS
RELESSER-T is a cross-sectional study, recording cumu-
lative clinical data until the last medical visit and the status of
the disease and treatments at this time. Its design and the
methods have been described in detail elsewhere.10 In short,
45 Rheumatology Units throughout Spain participated in the
study. All of the participating centers belong to the same
national public healthcare system and thus have the same
resources at their disposal. All clinicians involved in the study
were expert rheumatologists in SLE. They were asked to include
subjects 16 years of age or older, and who met 4 or more of the
1997 ACR SLE criteria (SLE),9,11 as well as patients who
fulfilled just 3 criteria, but who had been diagnosed with
SLE by an experienced rheumatologist (iSLE). The first patient
was enrolled in October 2011 and data collection was completed
in August 2012. Patients were widely and homogeneously
distributed across Spain, thus avoiding selection bias. Bearing
in mind that virtually all patients with SLE treated in our
country are referred to hospitals, the possibility of center
selection bias was minimal.
Patients lacking at least 50% of the defined ‘‘minimal
essential data’’ were excluded. Data were obtained by reviewing
clinical histories and the information was electronically col-
lected using an ad hoc online application.
In order to ensure that the data were homogenous and of
high quality, every item in the protocol had a highly standar-
dized definition, all participants had online access to guidelines
on how to complete the registration process, and all were trained
and evaluated beforehand in the use of the different indices used
to assess the disease. Once the electronic enrolment was com-
pleted, and the data reviewed and corrected if necessary, the
registry was locked down. A review of the database was carried
out by a professional monitor with experience in rheumatologic
Medicine  Volume 94, Number 1, January 2015studies. Any and all mistakes were discussed with the principal
investigators and final discrepancies were sent to the sub-
investigators for resolution.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Copiables and Definitions
Three hundred fifty-nine variables per patient were col-
ted. Variables were divided into several groups:1 Demographic data: age, gender, and ethnicity.
Chronology: time of first symptom and diagnosis of SLE,
follow-up.
Cumulative manifestations as defined in (1) the ACR
classification criteria for SLE,9,11 (2) the activity index
SLEDAI (Systemic Lupus Erythematosus Disease Activity
Index)12 in the BILAG (British Isles Lupus Assessment
Group) Index,13,14 and (3) the SLICC/ACR DI (Systemic
Lupus International Collaborative Clinics/American Col-
lege of Rheumatology Damage Index).15
SLE status, using the activity index SELENA-SLEDAI
(Safety of Estrogens in Systemic Lupus Erythematosus
National Assessment-SLEDAI)16; damage, using the
SLICC/ACR Damage Index (SLICC/ACR/DI)15; and
severity, using the Katz Index (SKI), range 0 to 13.17
Coexistence of antiphospholipid syndrome, as defined by
the Sydney classification criteria18; mixed connective tissue
disease, as defined by Alarco´n-Segovia criteria19; or Sjo¨gren
syndrome if the patient presented sicca syndrome and a
positive Schirmer test, as well as typical changes in
scintigraphy or a positive labial biopsy.6 Comorbidities, including severe infections and conditions
described in the Charlson Comorbidity Index.207 Laboratory findings, imaging or pathological studies.
8 Any treatments undergone and the reason for discontinu-
ation, if applicable.
9 Refractory SLE: defined as inefficacy of cyclophosphamide
(CYC), use of rituximab, splenectomy, or inefficacy of 2 or
more immunosuppressives (methotrexate, leflunomide,
abatacept, anti-TNF, azathioprine, mycophenolate mofetil,
and/or mycophenolic acid).
A clinical or laboratory finding was considered noteworthy
if the patient presented it at any time during the course of
the disease.tistical Analysis
Relative and absolute frequencies for qualitative variables
re calculated, as were mean and standard deviations or
BLE 1. Demographic and Chronological Characteristics of iSL
N iSLE SL
ale, N (%) 4016 292 (84.9) 3315 (90.
casians, N (%) 3905 312 (94.0) 3326 (93.
e at diagnosis mean (SD) 3990 42.9 (16.8) 34.6 (14.
e at first symptom mean
SD)
3919 41.0 (SD: 17.2) 32.6 (SD
gnostic delayy median
p25–p75)
3923 7.0 (2.0–26.0) 5.0 (1.0
low-upz median (p25–p75) 3827 67.0 (23.3–125.0) 102.0 (46.
ease duration§ median
p25–p75)
3846 8.0 (3.0–13.0) 12.0 (6.0
SLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete Siste
Adjusted odds ratio by gender, age at first symptom, and disease dura
Delay between first symptom and diagnosis, months.
Follow-up at a rheumatology unit, months.
Disease duration, years.
yright # 2015 Wolters Kluwer Health, Inc. All rights reserved.median and interquartile ranges for the quantitative variables,
depending on whether the distribution was normal or not.
Differences between values due to the number of ACR criteria
fulfilled (<4 or 4) were analyzed using a Student’s t test for
normal quantitative variables and a Mann–Whitney test for
abnormal variables. Chi-square was calculated for qualitative
independent variables, with corrections made with a Yates or
Fisher’s exact test for dichotomous variables.
Finally, to investigate the risk factors associated with an
iSLE status, we used a case–control design. An analysis based
on the estimation of simple and adjusted (by gender, age at
onset, and disease duration, for all of the variables studied) odds
ratios (ORs) by means of logistic regression with 95% confi-
dence intervals (95% CI) was carried out; P values <0.05 were
considered significant. The analysis was performed using the
statistical package SPSS 21.0 for Windows (SPSS, Chicago,
IL).
Ethical Issues
RELESSER adheres to the principles established by the
Declaration of Helsinki21 and the Protocol of Oviedo.22 Con-
fidentiality was respected in full accordance with Spanish law23.
In addition, the study was approved by the local
ethics committees.
RESULTS
A total of 4024 patients were included; 3679 (91.4%)
patients were SLE and 345 (8.5%) iSLE. Ninety percent were
women, the mean age at diagnosis was 35.4 (SD: 15.1) years,
and the median duration of disease was 11.0 years with an
interquartile range (IQ) of 6.0 to 19.0 years. The rest of the
demographic and chronological data contained in the RELES-
SER registry is described elsewhere.10
In the RELESSER registry, SLE patients experienced their
first symptom at a younger age and were also typically younger
when the diagnosis was first made. However, the delay between
the first symptom’s appearance and diagnosis was similar in
both groups. Disease duration and follow-up were longer in SLE
subjects than iSLE ones (Table 1).
A Systemic Lupus Erythematosus Cohort From SpainThe ACR criteria frequencies are shown in Table 2. The
most common SLE clinical manifestation in both groups (SLE
and iSLE) was arthritis. All ACR criteria had a higher
E and SLE Patients (Bivariate and Multivariate Analyses)
E P OR [95% CI] OR

[95% CI] P
3) 0.002 1.65 [1.21–2.27] — —
1) 0.617 1.16 [0.72–1.85] 1.20 [0.2–1.99] 0.490
6) <0.001 0.97 [0.96–097] 0.92 [0.90–0.96] <0.001
: 14.5) <0.001 0.97 [0.9–0.97] — —
–24.0) 0.467 1.00 [1.00–1.00] 0.99 [0.99–1.00] <0.001
0–170.0) <0.001 1.00 [1.00–1.00] 1.00 [1.00–1.00] 0.439
–19.0) <0.001 1.07 [1.05–1.08] — —
mic Lupus Erithematosus.
tion.
www.md-journal.com | 3
TABLE 2. ACR SLE Criteria Fulfilled in iSLE and SLE Patients
N iSLE, N (%) SLE, N (%) P OR [95% CI] OR

[95% CI] P
Malar rash 3963 37 (11.0) 2004 (55.2) <0.001 9.94 [7.02–14.07] 9.14 [6.20–13.46] <0.001
Discoid rash 3928 24 (7.1) 753 (21.0) <0.001 3.45 [2.26–5.26] 3.09 [1.98–4.82] <0.001
Photosensitivity 3901 68 (20.5) 2172 (60.8) <0.001 6.00 [4.56–7.91] 5.36 [4.00–7.19] <0.001
Oral ulcers 3898 24 (7.3) 1645 (46.1) <0.001 10.91 [7.16–16.61] 9.37 [6.08–14.45] <0.001
Arthritis 3963 148 (44.2) 2827 (77.9) <0.001 4.46 [3.54–5.61] 3.95 [3.09–5.04] <0.001
Serositis 3875 29 (8.8) 997 (28.1) <0.001 4.06 [2.76–5.99] 3.90 [2.60–5.86] <0.001
Renal disorder 3783 14 (4.3) 1112 (32.1) 0.001 10.49 [6.11–18.01] 9.12 [5.18–16.07] <0.001
Neurological disorder 3918 4 (1.2) 294 (8.2) <0.001 7.30 [2.70–19.70] 5.41 [1.99–14.69] <0.001
Hematological disorder 3764 131 (43.5) 2762 (79.8) <0.001 5.11 [4.01–6.52] 4.77 [3.69–6.16] <0.001
Immunological disorder 3359 145 (55.1) 2657 (85.8) <0.001 4.93 [3.79–6.41] 4.56y [3.44–6.04] <0.001
ANA 4012 323 (94.7) 3637 (99.1) <0.001 5.96 [3.33–10.67] 5.70 [2.97–10.91] <0.001
Bivariate and multivariate analyses. iSLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete Sistemic Lupus Erithematosus.
.
Ru´a-Figueroa et al Medicine  Volume 94, Number 1, January 2015prevalence among SLE patients. Moreover, although all of the
ACR criteria were associated with SLE, this association was
remarkably high in cases of malar rash, oral ulcers, and renal
disorder. The presence of antiphospholipid syndrome also
correlated with an SLE status (OR: 1.54; 95% CI: 1.03–
2.32; P< 0.04), as well as pregnancy morbidity (OR: 2.19;
95% CI: 1.11–4.34; P< 0.03) and anticardiolipin IgM or IgG
antibodies (Ab) (OR: 1.36; 95% CI: 1.02–1.82; P< 0.04).
However, there were no differences between the two groups
in terms of arterial, venous or small vessel thrombosis, anti-beta
2 glycoprotein Ab, and lupus anticoagulant.
Most SLE manifestations were more often found in SLE
patients (Table 3). Osteoarticular and mucocutaneous manifes-
tations, excepting cutaneous ulcers, were all associated with
SLE.
If considered individually, the frequency of respiratory
manifestations such as pleuritis, interstitial alveolitis, alveolar
hemorrhage, pulmonary hypertension (PHT), as defined by
SLICC/ACR/DI criteria or PTH in echocardiography, lung or
pleural fibrosis, and shrinking lung syndrome was no different
between the two groups. When general respiratory involvement
(any of the above manifestations) was globally considered,
however, it was more prevalent in SLE patients. This was
similarly true of cardiac and vascular involvement. In general,
although such respiratory complications were more frequent in
SLE subjects, when these manifestations were analyzed indi-
vidually, only valvular dysfunction (OR: 3.49; 95% CI: 1.09–
11.22; P< 0.04) and Raynaud (OR: 1.74; 95% CI: 1.29–2.35;
P< 0.01) were associated with SLE (adjusted OR).
Lupus nephritis, as defined by clinical or laboratory altera-
tions with or without renal biopsy, was much more prevalent in
SLE patients. In fact, 30.3% of SLE subjects present it versus
6.3% iSLE patients. In terms of the relative frequencies of the
different patterns of pathological findings, however, there were
no differences between the two groups. Class IV (WHO)
glomerular disease was the most frequently occurring form
of lupus nephritis in renal biopsies (29.4% in iSLE and
48.6% in SLE patients). The association of end-stage renal
disease, as defined by SLICC/ACR/DI and SLE status, did not
reach statistical significance (adjusted OR: 2.04; 95% CI: 0.63–

OR adjusted by gender, age at first symptom, and disease duration
y 20.1% of values lost.6.56; P¼ 0.23) (Table 3).
Neuropsychiatric involvement as a whole and seizures in
particular were both associated with SLE. Ophthalmological
4 | www.md-journal.comsymptoms others than keratoconjunctivitis sicca, such as visual
alteration, cataracts, retinopathy or uveitis, were all associated
with SLE. They were found in 15% of SLE patients and in
nearly 10% of iSLE patients. Most laboratory manifestations,
such as hematological alterations, low complement levels, and
above all the presence of autoantibodies were also associated
with SLE status (Table 3).
Hospitalizations, refractoriness, and mortality were associ-
ated with SLE. Furthermore, SLE patients died younger than
iSLE ones [55.8 (18.0) vs 71.7(9.0) years], although deaths due
to SLE activity did not differ between the two groups (Table 4).
Differences in comorbidity were also explored. Severe
infection was associated with SLE. The proportion of patients
that smoked or had smoked in the past exceeded 40% in both
groups. Although the prevalence of arterial hypertension was
higher in SLE patients, there were no differences regarding
cardiovascular events or dyslipoproteinemia. Diabetes mellitus
(DM) was associated with iSLE (Table 5). Charlson index
values were identical in both groups [median: 2 (IQ: 1–3)].
Activity, damage, and severity index scores were higher in
the SLE than in iSLE group [median SELENA-SLEDAI 2 (IQ:
0–4) vs 0 (0–2), median SLICC/ACR/DI 1 (0–2) vs 0 (0–1)
and SKI 2 (1–3) vs 1 (1–2)] (Figure 1). Additionally, when the
analysis was adjusted for gender, age at onset, and disease
duration, higher activity, damage and SKI remained more
strongly associated with SLE [(OR: 1.14; 95% CI: 1.08–
1.20; P< 0.01); (OR: 1.29; 95% CI: 1.15–1.44; P< 0.00);
(OR: 2.10; 95% CI: 1.83–2.42; P< 0.01)].
An analysis of the various treatments used showed that
although themajority of patients in both groups received or had
received corticosteroids (88.9% in SLE vs 69.1% in iSLE) and
antimalarials (83.3 vs 69.4%), all such treatments were more
commonly associated with SLE (Table 6). One-third of SLE
subjects were, or had been on, azathioprine versus just 13.2%of
iSLE patients. Statistical differences were also found in terms
of treatments involving CYC, mycophenolate mofetil, and
rituximab. Approximately 15% of patients received metho-
trexate, without differences being noted between the two
groups.
Treatment with angiotensin-converting enzyme inhibitors,
statins, diuretics, and anti-osteoporotic agents were all associ-
ated with SLE, while acetylsalicylic acid, oral anticoagulants,
and oral hypoglycemic agents were not (Table 5).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Organ Involvement in iSLE and SLE Patients
N iSLE, N (%) SLE, N (%) P OR [95% CI] OR

[95% CI] P
Weight loss 3952 18 (5.4) 358 (9.9) 0.009 1.93 [1.19–3.15] 2.03 [1.22–3.39] 0.006
Adenopathy 3945 11 (3.3) 374 (10.4) <0.001 3.39 [1.84–6.25] 2.96 [1.60–5.48] 0.001
Inflammatory rash 3962 92 (27.2) 2390 (65.9) <0.001 5.18 [4.04–6.64] 4.38 [3.36–5.72] <0.001
Alopecia 3933 54 (16.2) 1291 (35.9) <0.001 2.90 [2.15–3.91] 2.23 [1.62–3.06] <0.001
Cutaneous ulcers 3966 3 (0.9) 104 (2.9) 0.047 3.32 [1.05–10.51] 3.83 [0.93–15.80] 0.064
Any osteoarticular manifestation

3917 160 (49.1) 2877 (80.1) <0.001 4.18 [3.32–5.27] 3.74 [2.92–4.78] <0.001
Avascular necrosis 3959 3 (0.9) 151 (4.2) 0.004 4.89 [1.51–15.42] 4.65 [1.14–19.02] 0.033
Any respiratory manifestationy 3648 48 (15.8) 1056 (30.6) <0.001 2.46 [1.79–3.38] 2.55 [1.82–3.58] <0.001
Any cardiac manifestationz 3650 53 (17.3) 943 (28.2) <0.001 1.88 [1.38–2.55] 1.73 [1.25–2.39] 0.001
Myocardial infarction 3962 12 (3.5) 71 (2) 0.081 0.55 [0.29–1.02] 0.68 [0.35–1.33] 0.257
Peripheral vascular disease§ 3863 75 (22.9) 1329 (37.6) <0.001 2.02 [1.55–2.64] 1.65 [1.24–2.19] 0.001
Raynaud 3879 64 (19.1) 1200 (33.9) <0.001 2.17 [1.64–2.87] 1.74 [1.29–2.35] <0.001
Lupus nephritis 3930 21 (6.3) 1101 (30.6) <0.001 6.60 [4.22–10.33] 5.69 [3.53–9.16] <0.001
End-stage renal disease
(SLICC/ACR/DI)
3872 3 (0.9) 99 (2.8) 0.059 3.17 [1.00–10.04] 2.04 [0.63–6.56] 0.232
Neuropsychiatric symptoms 3743 46 (14.9) 764 (22.2) 0.004 1.63 [1.18–2.25] 1.46 [1.04–2.04] 0.030
Seizures (SLICC/ACR/DI) 3752 2 (0.6) 189 (5.2) <0.001 9.25 [2.29–37.44] 7.22 [1.77–29.43] 0.006
Ophthalmological manifestations

3832 32 (9.9) 530 (15.1) 0.015 1.61 [1.10–2.35] 1.82 [1.19–2.77] 0.006
Retinopathy 3935 7 (2.1) 162 (4.5) 0.049 2.23 [1.04–4.79] 1.58 [0.73–3.45] 0.248
Hematological manifestationsyy 3025 151 (48.7) 2888 (81.0) <0.001 4.48 [3.53–5.68] 4.35 [3.38–5.60] <0.001
Low complement 3934 183 (54.1) 2804 (78.0) <0.001 3.00 [2.39–3.77] 2.38 [1.86–3.06] <0.001
Anti Ro Ab 3888 105 (31.9) 1403 (39.4) 0.009 1.39 [1.09–1.77] 1.39 [1.07–1.81] 0.012
Anti La Ab 3883 48 (14.7) 690 (19.4) 0.044 1.40 [1.02–1.92] 1.45 [1.03–2.05] 0.032
Anti RNP Ab 3866 38 (11.7) 891 (25.2) <0.001 2.55 [1.80–3.61] 2.25 [1.56–3.25] <0.001
Sjo¨gren’s syndrome 3937 33 (9.7) 517 (14.4) 0.023 1.56 [1.07–2.26] 1.60 [1.08–2.37] 0.019
iSLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete Sistemic Lupus Erithematosus.
Myositis, amioatrophy, arthritis, or tendon rupture.
yPleuritis, interstitial alveolitis, alveolar haemorrhage, pulmonary hypertension (PHT) defined by SLICC/ACR/DI/ACR/DI or PHT in echo-
cardiography, lung or pleural fibrosis, or shrinking lung syndrome.
zMyocarditis, valvular dysfunction, Libman-Sacks endocarditis, vasculitis, ischemic cardiopathy, or pericarditis.
§ Lower limb claudication, tissue loss, venous thrombosis, or Raynaud.
 psy
thro
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RELESSER is a large multicenter registry of SLE patients
from the European population, created by SER, with high
quality and homogeneous data.10 The narrow confidence inter-
vals in the results presented here underscore the reliability and
accuracy of the data drawn from this register. In this study, we
Organic brain syndrome, cephalea, neuropathy, cognitive damage,
Visual alteration, cataracts, retinopathy, or uveitis.
yyAnemia, leucopenia, lymphopenia, thrombocytopenia, thrombotichave carried out a detailed cross-sectional description of
the patients included in the RELESSER registry, focusing on
the differences between SLE and iSLE, and providing the
TABLE 4. Bivariate and Multivariate Analyses of Mortality and Oth
N iSLE N (%) dSLE N (
Hospitalization by SLE activity 3932 94 (28.0) 1965 (44
Deaths 3695 15 (4.7) 211 (6.3
Death due to SLE activity — 5 (33.3) 55 (26
Age at death (mean (SD) — 71.7 (9.0) 55.8 (18
Refractory SLE 4024 25 (7.2) 900 (23
iSLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete Siste
Adjusted odds ratio by gender, age at first symptom and disease durat
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.largest iSLE cohort assembled now available. We consider this
a very pertinent exercise, since iSLE is not a rare condition. In
our registry, nearly 10% of the patients diagnosed with SLE by
experts should be more properly classified as iSLE. In fact, in
the only epidemiologic population-based study published to
date, the prevalence of iSLE was about one-quarter that of SLE
in the same region.24
chosis, stroke, or myelitis.
mbocytopenic purpura, red cell aplasia, or hemophagocytic syndrome.In our study, there were differences between the two
groups with respect to sex and age. It is known that both age
at onset and gender modify disease expression.1,25 In addition,
er Variables Related to Complications in SLE and iSLE Patients
%) P OR [95% CI] OR

[95% CI] P
.6) <0.001 3.10 [2.42–3.97] 2.79 [2.15–3.63] <0.001
) 0.314 1.36 [0.80–2.33] 2.25 [1.24–4.08] 0.008
.1) 0.551 0.71 [0.23–2.15] 0.40 [0.09–1.70] 0.212
.0) <0.001 0.94 [0.90–0.98] 0.62 [0.43–0.88] 0.007
.0) <0.001 4.15 [2.74–6.27] 3.04 [1.98–4.68] <0.001
mic Lupus Erithematosus.
ion.
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TABLE 5. Differences in Comorbidities Between iSLE and SLE Patients
N iSLE, N (%) SLE, N (%) P OR [95% CI] OR

[95% CI] P
Smoking 3610 139 (46.6) 1362 (41.1) 0.073 0.80 [0.63–1.01] 0.80 [0.62–1.04] 0.092
DM 3962 29 (8.5) 179 (4.9) 0.007 0.56 [0.37–0.84] 0.68 [0.44–1.06] 0.09
DL 3859 99 (30.3) 1106 (31.3) 0.745 1.05 [0.82–1.34] 1.16 [0.89–1.52] 0.269
HTN 3983 70 (20.7) 1069 (29.3) 0.001 1.59 [1.21–2.09] 1.88 [1.38–2.56] <0.001
Cardiovascular eventsy 3916 30 (9.1) 368 (10.3) 0.550 1.15 [0.78–1.70] 1.53 [0.98–2.38] 0.062
Severe infection 3795 30 (9.6) 725 (20.8) <0.001 2.49 [1.69–3.66] 2.16 [1.45–3.23] <0.001
Malignancy 3961 18 (5.4) 209 (5.8) 0.875 1.07 [0.65–1.76] 1.21 [0.71–2.06] 0.484
Lymphoma 3961 1 (0.3) 20 (0.6) 0.99 1.85 [0.25–13.80] 2.08 [0.27–15.95] 0.482
DL¼ dyslipoproteinemia, DM¼ diabetes mellitus, HTN¼ hypertension, iSLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete
Sistemic Lupus Erithematosus.
Ru´a-Figueroa et al Medicine  Volume 94, Number 1, January 2015disease duration has a significant impact on various parameters

OR adjusted by gender, age at onset, and disease duration.
y Stroke or heart attack or peripheral arteriopathy.such as accrual of clinical manifestations, damage and rate of
complications. To avoid these confounding factors, adjusted
analyses by gender, age at onset, and disease duration, for all of
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FIGURE 1. Charlson comorbidity index, SELENA-SLEDAI index, SLIC
grouped according to diagnostic category iSLE¼ incomplete Sistemi
tosus.
6 | www.md-journal.comthe variables studied, were carried out. Although disease
duration was longer in the SLE population, that of the RELES-
SER iSLE patients was similarly long; that is, 8 years, which
allowed for an adequate characterization of this patient
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c Lupus Erithematosus, SLE¼ complete Sistemic Lupus Erithema-
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 6. Treatments Received by iSLE and SLE Patients
N iSLE, N(%) SLE, N (%) P OR [95% CI] OR

[95% CI] P
Corticosteroids 3823 224 (69.1) 3112 (88.9) <0.001 3.59 [2.77–4.65] 3.22 [2.43–4.25] <0.001
Methotrexate 3798 44 (13.8) 579 (16.6) 0.207 1.25 [0.90–1.74] 1.22 [0.86–1.74] 0.268
Leflunomide 3657 8 (2.5) 128 (3.7) 0.360 1.48 [0.72–3.06] 1.22 [0.58–2.55] 0.596
Azathioprine 3785 42 (13.2) 1143 (33.0) <0.001 3.25 [2.33–4.52] 2.46 [1.73–3.50] <0.001
Cyclophosphamide 3793 20 (6.3) 780 (22.5) <0.001 4.35 [2.74–6.88] 3.47 [2.12–5.67] <0.001
Mycophenolate mofetil 3774 13 (4.0) 525 (15.0) <0.001 4.25 [2.42–7.46] 3.45 [1.91–6.25] <0.001
Antimalarials 3806 225 (69.4) 2899 (83.3) <0.001 2.19 [1.70–2.82] 1.91 [1.45–2.51] <0.001
Intravenous immunoglobulin 3755 10 (3.1) 154 (4.5) 0.326 1.45 [076–2.78] 1.14 [0.59–2.23] 0.693
Rituximab 3791 5 (1.6) 227 (6.5) <0.001 4.38 [1.79–10.70] 3.34 [1.36–8.23] 0.009
Acetylsalicylic acid 3222 88 (32.6) 1097 (37.2) 0.154 1.22 [0.94–1.60] 1.16 [0.88–1.54] 0.289
Oral anticoagulants 3764 37 (11.6) 497 (14.4) 0.193 1.29 [0.90–1.83] 1.37 [0.93–2.02] 0.113
Plasmapheresis 3801 1 (0.3) 56 (1.6) 0.087 5.23 [0.72–37.93] 4.22 [0.57–31.04] 0.157
Dialysis 3774 2 (0.6) 102 (3.1) <0.021 4.98 [1.22–20.26] 3.33 [0.81–13.70] 0.095
Statins 3645 58 (18.8) 847 (25.4) 0.013 1.47 [1.09–1.97] 1.43 [1.04–1.95] <0.026
Angiotensin-converting
enzyme inhibitors
3635 48 (15.4) 1045 (31.4) <0.001 2.51 [1.83–3.45] 2.58 [1.85–3.61] <0.001
Diuretics 3604 25 (11.5) 732 (22.2) <0.001 2.20 [1.53–3.16] 2.41 [1.65–3.53] <0.001
Anti-osteoporotic agents 3682 55 (17.5) 831 (24.7) 0.006 1.54 [1.14–2.09] 1.63 [1.17–2.28] 0.004
iSLE¼ incomplete Sistemic Lupus Erithematosus, SLE¼ complete Sistemic Lupus Erithematosus.
case
Medicine  Volume 94, Number 1, January 2015 A Systemic Lupus Erythematosus Cohort From Spainsubgroup. As was perhaps expected, SLE patients presented
more manifestations and complications than iSLE subject. The
presence of malar rash and oral ulcers was highly prevalent in
SLE patients, and both conditions are considered risk factor for
SLE progression, as has been documented in previous studies.6,8
The rate of renal and severe neurological disease was very low
in iSLE subjects (4% and 1.2%, respectively). Our adjusted
analysis showed higher activity, damage, severity, and global
mortality in SLE patients than in those with iSLE. The risk of
hospitalization due to SLE activity was lower in iSLE patients,
based on their minor index of severity. In addition, a greater
number of SLE patients received glucocorticoids, cyclopho-
sphamide, mycophenolate mofetil, and rituximab. Although
antimalarials are always recommended in SLE, and while most
iSLE patients should probably have been treated with such
drugs, up to 30% never received antimalarials, in contrast with
11% of SLE patients who did. Perhaps low awareness or
reluctance to prescribe the drug in patients with a less than
certain diagnosis could explain this difference. Refractoriness,
as defined by consensus in RELESSER, was also associated
with SLE.
Although activity and severity scores were low, 1 of every
4 deaths documented in RELESSER was due to SLE activity.
This mortality rate is an interesting discussion since it has never
been previously analyzed in the context of iSLE. Adjusted
mortality was higher in SLE patients, although there were no
differences between the two groups in terms of SLE activity-
related deaths. This intriguing finding, revealing such a striking
difference, may have several explanations. First of all, data
regarding cause of death were sometimes incomplete; thus,
confounding factor(s) may have played a role. Second, the
disease severity in iSLE patients might have been underesti-
mated. This could have resulted in a less closely monitored

Adjusted odds ratio by gender, age at onset, and disease duration.
yMultivariate analysis was not possible due to the small number offollow-up, as well as less immunosuppressive therapy, than
should have been undertaken. Furthermore, almost one-third of
iSLE patients were never prescribed antimalarials, and it is well
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.known that these drugs have beneficial and protective effects on
survival.26 In any case, the relatively low number of deaths
precludes the drawing of firm conclusions.
In regards to comorbidity—another topic not previously
studied in patients with iSLE—it is worth noting that no
differences were noted in the Chalrson Index, which was low
in both groups. Perhaps this index is not sufficiently sensitive to
identify all of the potential comorbidities in SLE and thus was
unable to detect any differences between the two groups. iSLE
patients suffer less severe infections, which may reflect the
milder disease states they experience, as well as the fact that
they receive less immunosuppressive drugs. In terms of cardi-
ovascular complications, the rates of angina or by-pass and
heart attack were numerically higher in iSLE subjects, although
without reaching statistical significance. iSLE patients were
typically older, and presented a higher rate of certain risk factors
for coronary disease (eg, smoking and DM), although, again, in
the multivariate analysis, such differences lost their statistical
significance. Besides, iSLE patients received less statins than
those with SLE, even though there were no differences with
respect to the prevalence of dyslipoproteinemia between the two
groups. This may reflect the lack of tight control over cardi-
ovascular risk factors in a subpopulation assumed to have a
milder form of the disease. As described previously,27 in the
RELESSER registry patients with hypertension were more
often SLE, which presumably reflects the higher incidence of
lupus nephritis found in these individuals.28
Consistent with our own results, several authors have
suggested that incomplete SLE may be a frequent, mild, and
relatively stable or benign form of the disease, apparently with a
minority of patients gradually evolving to SLE or other rheu-
matic disease,7,8,29 Other groups, however, have obtained
results consistent with the hypothesis that iSLE patients encom-
s.pass a subset that is likely to experience progressive organ
damage30 or to develop complete SLE.6 Swaak et al7 studied a
multicenter European cohort of patients with incomplete SLE.
www.md-journal.com | 7
Besides RELESSER, this is the only multicenter study available
on iSLE. This study included 122 patients with mean disease
duration of 4.5 years. Consistent with our results and with
virtually all of the studies completed to date, renal and central
nervous system involvement was low (16% and 3%, respect-
ively). Interestingly, even when patients eventually met the
ACR-SLE criteria in longitudinal studies, renal and neuropsy-
chiatric manifestations remained low.6–8 Median basal SLE
activity, as measured by SLEDAI, was 2.6 (4.5) in the Swaak
study. The figure was higher than in RELESSER iSLE
patients;7 38% of Swaak patients were on corticosteroids and
another 17% were on antimalarials vs RELESSER subjects
(69% on corticosteroids and another 69% on antimalarials).
This suggests a significant variability in clinical practice,
although disease duration at the time of enrollment was higher
in RELESSER patients. As with our patients, the low rate of
damage accrual in iSLE patients, compared to those with SLE,
has been previously reported.6,30
We have attempted to compare RELESSER SLE patient
characteristics not only with those from the EUROLUPUS
cohort, but also with the baseline characteristics of Caucasian
patients from the LUMINA and GLADEL cohorts. However, it
should be emphasized that differences in patient selection,
design, period of time when was conducted, and variable
definitions limits the validity of such comparison among these
various cohorts. The EUROLUPUS cohort included patients
from different European countries; specifically from the
internal medicine, rheumatology and nephrology units of only
4 Spanish referral centers. In contrast, RELESSER patients
were enrolled at 45 different rheumatology units spread across
the country, and thus more comprehensively reflects the current
reality of SLE in Spain and likewise a large southern European
area. Ninety-three point one percent of RELESSER patients
were Caucasian, reflecting the current demographics in
Spain, where most of the native population is Caucasian.31
In contrast, the EUROLUPUS PROYECT, which was carried
out in the 1990s, reported 97% of the Spanish population as
Caucasian.32 RELESSER patients were 33.3 (14.9) and 35.4
(15) years old at onset and diagnosis, respectively, which is
quite similar to the EUROLUPUS data. In the LUMINA
cohort, the mean age at diagnosis varied with ethnicity,
Caucasians tending to be older than African-Americans and
Hispanics [41.2 (14) vs 33.6 (12) vs 32.4 (13) years, respec-
tively].33 GLADEL is an inception cohort in which fulfillment
of 4 SLE ACR criteria was not mandatory. Here, patients were
of similar age at first symptom [29.5 (12) years] and at diagnosis
[31.1 (12) years] for the Caucasian subjects group.34 The
median time between first symptom and diagnosis in the
RELESSER group was 5.0 (0–618) months, which is similar
to the GLADEL registry figure of 6.0 (0.4–301) months. In
contrast, in the EUROLUPUS cohort the mean time between
first manifestation and final classification as SLE was 2 years.32
This difference could be explained by differences in the set of
criteria used for case definition (ie, ACR-1997 vs ACR-1982).
Musculoskeletal and hematological manifestations are the
most frequent symptoms in both RELESSER and GLADEL
patients, which means that these types of symptoms are the most
common at disease onset, as well as during disease evolution,
taking into account that median disease duration in the GLA-
DEL cohort was 34.2 (range: 0.9–333.0) months and in the
RELESSER cohort 148.0 (0–640) months. In EUROLUPUS
Ru´a-Figueroa et alpatients, who experienced a mean disease duration of 101 96
months, arthritis—followed by malar rash and fever—were the
most frequent symptoms.35
8 | www.md-journal.comThirty percent of RELESSER patients present some kind
of renal involvement, which was very similar to the Caucasian
population in the LUMINA cohort (32% of patients)36 and
somewhat lower than in the EUROLUPUS and GLADEL
registries (39% and 43.6%, respectively). These differences
may have stemmed from differences in ethnicity and/or patients
sources.
There are striking differences in the prevalence of ocular
manifestations. After 5 years of follow-up, only 1.7% of
EUROLUPUS patients continued to suffer retinopathy and
2.9% cataracts. One point one percent of GLADEL subjects
experienced uveitis, episcleritis, or scleritis. These manifes-
tations were more prevalent in the RELESSER group (15% of
SLE subjects), despite the fact that they were not actively
recruited; in fact, the incidence rate here is perhaps more in
keeping with what is commonly described in ophthalmological
consultations.37 Ocular manifestations of SLE are a reflection of
systemic disease38 and can lead to severe sight impairment,
including blindness.37 This signifies that ophthalmological
complaints, frequently overlooked, should be actively investi-
gated.
Global activity has been evaluated using the SELENA-
SLEDAI index in RELESSER patients, and baseline S-SLEDAI
was low: 2.6 (3.6). The LUMINA cohort was subject to a
different index for assessment of disease activity at baseline:
the SLAM (Systemic Lupus Activity Measure) index. Using the
SLAM index, Caucasians in the LUMINA cohort scored 8.5
(3.7).36 Although the scoring tools used differed, most likely
differences in baseline activity between the two groups was
insignificant.
Among the cumulative treatments administered in the
GLADEL cohort, corticosteroids were the most frequently used
(90.9%). Seventy-five percent of patients were treated with
antimalarials, and the immunosuppressive agent most often
used was cyclophosphamide (26.8%).34 As RELESSER and
GLADEL patients underwent similar regimens, it appears than
the drug treatment did not change with the duration of disease.
In other words, drug treatments for SLE patients were generally
introduced during the early years of disease. There was a
prominent difference in the EUROLUPUS data regarding anti-
malarial treatments. During the first 5 years of the EUROLU-
PUS study,39 only 40.2% of patients received them, in contrast
with 75% of RELESSER subjects. This could be due to
increased awareness about the benefits of antimalarials benefits
or to differences in approach among specialists involved in
caring for these patients.
The RELESSER registry has some limitations. The
method by which hospitals are chosen to participate in the
study, involving rheumatologist specially dedicated to SLE
clinical investigation, could introduce some selection bias.
Patients seen at these centers may have a more severe form
of the disease or may be under stricter care. There may be
differences between referral criteria, depending on the level of
care or the involvement of certain systems that lead certain
patient to particular specialists. In any case, the big sample size
and the number and characteristics of the participating units
across Spain helped minimize any such selection bias. Another
limitation of the present study concerns the incomplete follow-
up evident at the rheumatology units. Nonetheless, as the delay
between first symptom and rheumatologic evaluation and diag-
nosis remained relatively short, the loss of information should
Medicine  Volume 94, Number 1, January 2015not have significant ramifications.
However, the most important limitation of the RELESSER
registry is its retrospective design, which supposes a higher
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
possibility of measurement mistakes and which lacks sufficient
information regarding confounding variables.
However, some prospective studies are now being con-
ducted, with a focus on specific patient groups from the
RELESSER registry. The ongoing prospective phase of the
registry also includes one study involving a cohort of iSLE
patients. Such prospective studies will try to confirm any
associations between the different variables and activity,
damage, severity, mortality, and co-morbidities that become
apparent during multivariate analysis of the study’s transversal
Medicine  Volume 94, Number 1, January 2015phas1
2
7.
Cope.
CONCLUSIONS
RELESSER represents the largest European SLE registry
compiled to date, on that provides comprehensive, updated
and reliable information on SLE manifestations, disease
status, and comorbidity conditions and treatments in daily
clinical practice.
There are two well-differentiated groups of patients: SLE
and iSLE. Although iSLE patients typically present a stable,
mild form of the disease with a low rate of major organ
involvement and low refractoriness, lupus-caused mortality
does not seem to differ between these two groups, with iSLE
patients warranting adequate treatment and follow-up.
3 SLE in the southern European population does not seem to
differ from other Caucasian populations, being similar in
terms of low activity levels and severity grades.
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